Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.82 USD
Change Today 0.00 / 0.00%
Volume 0.0
TRVN On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

trevena inc (TRVN) Snapshot

Open
$5.87
Previous Close
$5.82
Day High
$6.11
Day Low
$5.80
52 Week High
03/24/15 - $8.16
52 Week Low
12/9/14 - $3.80
Market Cap
229.1M
Average Volume 10 Days
175.4K
EPS TTM
$-1.80
Shares Outstanding
39.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TREVENA INC (TRVN)

Related News

No related news articles were found.

trevena inc (TRVN) Related Businessweek News

No Related Businessweek News Found

trevena inc (TRVN) Details

Trevena, Inc., a clinical stage biopharmaceutical company, discovers, develops, and intends to commercialize therapeutics for G protein coupled receptors. The company’s central nervous system product pipeline includes TRV130, a small molecule G protein biased ligand at the mu-opioid receptor, which is in Phase II clinical trials for patients experiencing moderate to severe acute pain where IV administration is preferred; and TRV734, a small molecule G protein biased ligand at the mu-opioid receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain. Its central nervous system product pipeline also comprises TRV250, a small molecule G protein biased ligand of the delta-opioid receptor, which is in preclinical development stage for the treatment-refractory migraine headaches. In addition, the company develops cardiovascular programs, such a TRV027, a peptide beta-arrestin biased ligand that targets the angiotensin II type 1 receptor and is in Phase II clinical trials for the treatment of acute heart failure in combination with standard diuretic therapy. Trevena, Inc. was founded in 2007 and is headquartered in King of Prussia, Pennsylvania.

42 Employees
Last Reported Date: 03/18/15
Founded in 2007

trevena inc (TRVN) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $686.7K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $465.3K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $469.2K
Compensation as of Fiscal Year 2014.

trevena inc (TRVN) Key Developments

Trevena, Inc. Appoints Yacoub Habib as Senior Vice President, Business Development and Corporate Planning

Trevena, Inc. announced the appointment of Yacoub Habib, Ph.D., M.B.A., as senior vice president, business development and corporate planning. Dr. Habib will lead the company’s partnering and licensing initiatives. Dr. Habib joins the company from Ikaria, Inc. where he served as vice president of business development and led the business development strategy for the company until its acquisition. From 2007 to 2009, he served as executive director of new business development for Pfizer and participated in the creation of new business development strategies in areas outside of Pfizer’s core competency markets.

Trevena Announces Board and Compensation Committee Changes

On June 29, 2015, Francois Nader, M.D., provided Trevena, Inc. with notice of his intention to resign from the Board of Directors of the company, effective as June 30, 2015. At the time of his resignation, Dr. Nader also was serving as the Chair of the Compensation Committee of the Board. In connection with Dr. Nader's resignation, the Board (i) fixed the number of directors of the company at eight, (ii) appointed Anne M. Phillips, M.D., as a member of the Compensation Committee of the Board and (iii) appointed Barbara Yanni as Chair of the Compensation Committee of the Board, in each case effective as of June 30, 2015.

Trevena, Inc.(NasdaqGS:TRVN) added to Russell 2000 Index

Trevena, Inc. will be added to Russell 2000 Index

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRVN:US $5.82 USD 0.00

TRVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TRVN.
View Industry Companies
 

Industry Analysis

TRVN

Industry Average

Valuation TRVN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TREVENA INC, please visit www.trevenainc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.